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A gene expression signature meant to distinguish between
telomerase and alternative lengthening of telomeres (ALT)
utilization was recently described (Lafferty-Whyte et al.,
2009). This was generated from the intersection of two
independent signatures obtained from cell lines and
liposarcoma tumors, respectively, which utilize different
telomere maintenance mechanisms (TMMs). To assess
the utility of this signature, we used U133plus2.0 arrays
(Affymetrix, Santa Clara, CA, USA) to undertake a
similar analysis of an independent collection of lipo-
sarcomas with deﬁned TMMs (see GEO accession
GSE20559, which includes full details of the methods).
For our data set, use of the 297 gene signature causes
the liposarcomas to cluster not on the basis of TMM,
but rather on the basis of tumor histological subtype
(Figure 1a), consistent with the signatures reported by
others (Matushansky et al., 2008).
To control for the effect of histological subtypes, we
then restricted our analysis to dedifferentiated liposarco-
mas. Despite this constraint, when using linear modeling
for microarrays (Limma; (Smyth, 2004)) to assess
differential expression, we obtained no genes that are
signiﬁcantly changed, unless the data are pre-ﬁltered to
remove low-expressing non-varying probesets (cvo0.1
across the samples). The pre-ﬁltered data generated a
14-gene signature (threshold of false discovery rate-
corrected P-valueo0.1, fold-change>2), with no genes in
common with the 297-gene signature of Lafferty-Whyte
et al. (2009). This is in agreement with the previous
Figure 1 Heatmap visualizations of the 297 gene signature from Lafferty-Whyte et al. (2009) for all genes having a corresponding
Affymetrix probeset. Where more than one probeset was available, the one with the highest median expression across the dataset
was used as the exemplar. The data are GCRMA normalized and represented as cosine similarity on median-centered log-space data,
using average linkage clustering. Red and green correspond to increased versus decreased expression, respectively, as compared with
the experiment-wide median. Histological type (WD, well differentiated; MYX, myxoid; RC, round cell; DD, dedifferentiated; PLEO,
pleomorphic; LS NOS, liposarcoma not otherwise speciﬁed) and TMM are indicated, with ‘NA’ used for tumors that were not clearly
ALT or telomerase-positive. (a) Heatmap of 38 tumors representing all histological subtypes of liposarcoma. (b) Heatmap of only
dedifferentiated liposarcoma samples.
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study, where a similar approach failed to identify any
genes that are signiﬁcantly correlated with TMM, an
observation that motivated their use of Fisher’s exact
test to produce a list of >6700 differentially expressed
genes. We also performed unsupervised clustering of
the dedifferentiated tumor data corresponding to the
297-gene signature (Figure 1b) and found no strong
correlation between gene expression and TMM.
It is possible that the discrepancies between our data
and those of Lafferty-Whyte et al. (2009) reﬂect
differences in microarray platform or tumor samples
used. However, as the authors noted, the cell lines used
in their study differ not only in TMM, but also in tissue
of origin, with 75% of the telomerase-positive cell lines
being of epithelial origin and 75% of the ALT cell lines
being of ﬁbroblastic origin. The initial gene signature
obtained from comparing these two groups would be
expected to contain a strong signature reﬂective of cell
type, in addition to any putative TMM signature.
Likewise, although we note that the histological
subtypes of liposarcomas used to generate the 297 gene
signature were not speciﬁed in this publication, or in the
information uploaded into the GEO database, it can
be largely deduced from an earlier publication from
the same group (Cairney et al., 2008). Based on Table 1
in that report, we note that the ALT tumors are
predominantly dedifferentiated liposarcomas, whereas
the telomerase tumors are predominantly myxoid/round
cell liposarcomas. Thus, a comparison of ALT versus
telomerase tumors using this data set suffers from the
confounding effect of differing histological subtypes in
the two groups. Given the large-scale gene expression
changes seen between cells of different origin and tumors
of different histologies, it is perhaps not surprising that
the 297 gene signature contains a strong component
related to differentiation state, as shown in Figure 1a.
Dedifferentiated liposarcomas differ markedly from
myxoid liposarcomas; different genetic mechanisms drive
the formation of these two types of liposarcoma.
Dedifferentiated liposarcomas harbor complex karyotypes
commonly containing Chr.12q12–15 ampliﬁcation,
whereas 90% of myxoid/round cell liposarcomas are
characterized by a t(12;16)(q13–14;p11) translocation.
Indeed, translocation driven sarcomas are generally
telomerase positive, whereas those with complex karyo-
types utilize ALT at an appreciable frequency (Montgom-
ery et al., 2004; Ulaner et al., 2004), underscoring the bias
in the sample set analyzed. This likely introduces a major
confounding effect in their data set, with the set of ALT
tumors heavily biased for dedifferentiated liposarcomas.
As the expression signature of dedifferentiated liposarco-
ma more closely resembles mesenchymal stem cells than
does that of myxoid/round cell liposarcoma (Matushansky
et al., 2008), this may provide an explanation for their
ﬁnding that ALT tumors appear to cluster with the
mesenchymal stem cell samples. Certainly, our observation
that the 297 gene signature fails to distinguish tumors
based upon TMM in our independent set of tumors
comprising a single histological type of liposarcoma
suggests that this signature is not a robust indicator
of TMM. Instead, it is likely that this 297-gene signature
reﬂects differentiation differences associated with
varying histological subtypes of liposarcoma.
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